Sub Banner Image

Chinese Biotech Showcases Challenger to Eli Lilly’s Obesity Drug

Markets

Amber Tong

·

June 21, 2025

·

Bloomberg

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new challenger to blockbusters from Novo Nordisk A/S and Eli Lilly & Co.

More from

Bloomberg

More

Markets

Articles

Trending News

Enjoy premium content in your inbox.

You're in! Check your email to learn more.
Oops! Something went wrong while submitting the form.